BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.（BBIO）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BBIO · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
162
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
BridgeBio Pharma, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
BBIO 季度内部人买卖趋势
BBIO 内幕交易卖出 · BBIO 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · BBIO CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
BBIO 高管卖出股份 · BBIO 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 2,256 | $152K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 6,725 | $459K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 5,072 | $351K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 11,250 | $793K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 800 | $57K | Form 4 |
| May 16, 2026 | Trimarchi Thomas President and CFO | Other | 22,781 | $1.51M⚡ | Form 4 |
| May 18, 2026 | Trimarchi Thomas President and CFO | Sale | 10,456 | $678K | Form 4 |
| May 18, 2026 | Trimarchi Thomas President and CFO | Sale | 3,195 | $211K | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 6,519 | — | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 11,553 | — | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 19,599 | — | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Other | 36,236 | $2.40M⚡ | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 33,544 | — | Form 4 |
| May 16, 2026 | Apuli Maricel CAO | Other | 4,714 | $312K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Option | 10,000 | $168K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 6,200 | $413K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 2,088 | $141K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 1,512 | $103K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 200 | $14K | Form 4 |
| May 7, 2026 | Kumar Neil CEO · Director | Sale | 11,217 | $757K | Form 4 |
| May 7, 2026 | Kumar Neil CEO · Director | Sale | 8,334 | $570K | Form 4 |
| May 7, 2026 | Kumar Neil CEO · Director | Sale | 449 | $31K | Form 4 |
| May 8, 2026 | Kumar Neil CEO · Director | Sale | 13,974 | $931K | Form 4 |
| May 8, 2026 | Kumar Neil CEO · Director | Sale | 5,076 | $342K | Form 4 |
| May 8, 2026 | Kumar Neil CEO · Director | Sale | 950 | $65K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BBIO 内幕交易
BBIO 内幕交易
BridgeBio Pharma, Inc.（BBIO）内幕交易数据来源于公司内部人（包括Kumar Neil (CEO · Director), Scott Randal W. (Director), Trimarchi Thomas (President and CFO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。BBIO内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看BridgeBio Pharma, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BBIO 内幕交易 · 5个问题BridgeBio Pharma, Inc.（BBIO）的内部人包括高管和董事，如Kumar Neil (CEO · Director), Scott Randal W. (Director), Trimarchi Thomas (President and CFO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026